Biotech and pharma companies are racing to develop combinations of immunotherapy drugs to treat cancer more effectively. But new data emerging Wednesday night from clinical trial research abstracts released by the American Society of Clinical Oncology (ASCO) paint a muddled picture.
Even with hints of efficacy, there’s still no convincing proof cancer patients benefit more when experimental immune-boosting drugs are paired with immunotherapy blockbusters like Merck’s Keytruda and Bristol-Myers Squibb‘s Opdivo.
About the Author Reprints
Subscribing to STAT